Format

Send to

Choose Destination
J Virus Erad. 2016 Jul 1;2(3):149-55.

HIV pre-exposure prophylaxis for women.

Author information

1
Department of Medicine, Division of Infectious Diseases , Emory University School of Medicine and Grady Health System , Atlanta , GA , USA.
2
Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine , University of California San Francisco (UCSF) , San Francisco , CA , USA.

Abstract

Women and girls comprise nearly half of HIV-infected individuals globally and 20% of new infections in the United States, indicating an urgent need to optimise HIV prevention options in this population. HIV pre-exposure prophylaxis (PrEP) - where antiretrovirals are administered to HIV-non-infected individuals at risk of HIV acquisition - is a promising, female-controlled HIV prevention strategy but has so far been underutilised in women. Clinical trial data demonstrate efficacy of daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for reduction of HIV acquisition among women when used consistently. Limited HIV risk perception and suboptimal PrEP awareness among women and healthcare personnel are among the challenges with PrEP delivery for women. Future research into the development of new drugs and delivery systems, and integrating PrEP delivery with reproductive healthcare services, provide opportunities to optimise this prevention strategy for women.

KEYWORDS:

HIV prevention; Pre-exposure prophylaxis; women's health

PMID:
27482454
PMCID:
PMC4967966

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center